1h Free Analyst Time
The radiopharmaceuticals market is forecasted to grow by USD 4612.62 mn during 2022-2027, accelerating at a CAGR of 10.22% during the forecast period. The report on the radiopharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a rising incidence of neurological disorders, growing cancer cases rising investment in the oncology market, and minimal side effects of radiopharmaceuticals.
The radiopharmaceuticals market is segmented as below:
By Source
- Cyclotrons
- Nuclear reactors
By End-user
- Diagnostics
- Therapeutics
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the radiopharmaceuticals market covers the following areas:
- Radiopharmaceuticals market sizing
- Radiopharmaceuticals market forecast
- Radiopharmaceuticals market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Source
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global radiopharmaceuticals market: Bayer AG, Bracco Spa, Cardinal Health Inc., Curium Pharma, Eckert and Ziegler AG, General Electric Co., IBA Radiopharma Solutions, Jubilant Pharma Ltd., Lantheus Holdings Inc., Mallinckrodt Plc, NorthStar Medical Radioisotopes LLC, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings Corp., Positron Corp., Radiomedix Inc., Siemens AG, Sinotau Pharmaceuticals, Telix Pharmaceuticals Ltd., and Sotera Health Co..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is production of cyclotron-based radiopharmaceuticals.'
According to the report, one of the major drivers for this market is the rising incidence of neurological disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Bracco Spa
- Cardinal Health Inc.
- Curium Pharma
- Eckert and Ziegler AG
- General Electric Co.
- IBA Radiopharma Solutions
- Jubilant Pharma Ltd.
- Lantheus Holdings Inc.
- Mallinckrodt Plc
- NorthStar Medical Radioisotopes LLC
- Novartis AG
- NTP Radioisotopes SOC Ltd.
- PharmaLogic Holdings Corp.
- Positron Corp.
- Radiomedix Inc.
- Siemens AG
- Sinotau Pharmaceuticals
- Telix Pharmaceuticals Ltd.
- Sotera Health Co.
